Author:
Kang JongWook,Lee Geun Hyuk,Jung Yunu,Youn Dong Hyun,Lim Seona,Park Jinbong,Um Jae Young
Publisher
Springer Science and Business Media LLC
Subject
Health, Toxicology and Mutagenesis,Public Health, Environmental and Occupational Health,General Pharmacology, Toxicology and Pharmaceutics,Toxicology,Pathology and Forensic Medicine
Reference40 articles.
1. Carson, C. & Rittmaster, R. The role of dihydrotestosterone in benign prostatic hyperplasia. Urology 61, 2–7 (2003).
2. Lesovaya, E. A. et al. Rapatar, a nanoformulation of rapamycin, decreases chemically-induced benign prostate hyperplasia in rats. Oncotarget 6, 9718–9727 (2015).
3. Barkin, J. Benign prostatic hyperplasia and lower urinary tract symptoms: evidence and approaches for best case management. Can J Urol 18, 14 (2011).
4. Park, H. K. & Kim, S. K. Promoter polymorphisms of NDUFA4 gene were associated with prostate enlargement of benign prostatic hyperplasia. Mol Cell Toxicol 11, 401–406 (2015).
5. Steers, W. D. 5α-Reductase activity in the prostate. Urology 58, 17–24 (2001).
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献